• Sitemap
  • Contact us

pISSN 2384-2458 eISSN 2288-7261
Article View

Original Article

Lab Med Qual Assur 2021; 43(1): 31-36

Published online March 31, 2021

https://doi.org/10.15263/jlmqa.2021.43.1.31

Copyright © Korean Association of External Quality Assessment Service.

Development of a Method for Manufacturing External Quality Assessment Material for Genetic Testing of Solid Tumors Using Mutant and Wild-Type Cell Lines

Jinyoung Hong1 , Ji Hyun Kim1 , Seungman Park2 , Sang Gon Lee3 , Woochang Lee1 , Sail Chun1 , and Won-Ki Min1

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine; 2Seegene Medical Foundation, Seoul; 3Laboratory Medicine, Greencross Laboratories, Yongin, Korea

Correspondence to:Woochang Lee
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel +82-2-3010-4506
Fax +82-2-478-0884
E-mail wlee1@amc.seoul.kr

Received: September 23, 2020; Revised: November 18, 2020; Accepted: November 29, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: DNA extracted from mutant cell lines is frequently used as an external quality assessment (EQA) material for genetic testing of solid tumors because it is easy to obtain. However, the proportion of mutations in cell lines is different from that in actual tumor samples. In this study, mixtures of mutant DNA and wild-type DNA mimicking patient samples were analyzed to optimize the amount of mutant DNA in EQA specimens.
Methods: Four cell lines harboring the selected mutation were cultured, and genomic DNA was extracted from cultured cells. Wild-type cell line DNA was prepared in the same manner. Diluted samples were prepared by mixing each mutant cell line DNA and wild-type cell line DNA at different ratios. Sanger sequencing of target variants was performed. For reliability, sequencing was repeated three times and read by two readers. The cutoff was based on the lowest proportion of mutant DNA that was determined to be positive in all three experiments.
Results: The cutoffs of mutant cell line DNA ratios were 10%, 5%, 25%, and 25% for KRAS G12C, EGFR exon 19 deletion, EGFR T790M, and BRAF V600E, respectively. For the cell lines harboring EGFR T790M and BRAF V600E, the mutant fraction was not 100%.
Conclusions: When manufacturing EQA material for solid tumor genetic testing, consistent results can be obtained if the mutant proportion is 10% or more. In addition, the mutant allele frequency of the cell line should be checked in advance to guarantee that EQA materials contain enough mutant DNA.

Keywords: Genetic testing, Laboratory proficiency testing, Somatic variant

Supplementary File


Share this article on :

Stats or metrics